Showing 1911-1920 of 6037 results for "".
- New Spiral-Shaped Lens Designed to Improve Vision at Range of Distances and Lighting Conditionshttps://modernod.com/news/new-spiral-shaped-lens-designed-to-improve-vision-at-a-range-of-distances/2482108/French researchers have developed a spiral-shaped lens that is designed to maintain clear focus at different distances in varying light conditions. Published in the journal Optica,1 the researchers say the lens works much like progressive lenses used f
- New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDhttps://modernod.com/news/new-analysis-of-mri-findings-show-uplizna-reduced-the-formation-of-asymptomatic-optic-nerve-lesions-in-people-with-nmosd/2481467/Horizon Therapeutics announced the presentation of new MRI imaging data from the phase 3 clinical trial showing Uplizna (inebilizumab-cdon) reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). These findin
- Visionary Optics New Scleral Lens Design, Europa Tangenthttps://modernod.com/news/visionary-optics-new-scleral-lens-design-europa-tangent/2481375/Visionary Optics announced the launch of Europa Tangent, a scleral lens that combines a customizable design with a streamlined fitting process. The lens design is based on clinical experience and analysis of over 10,000 fittings driven by profilometry data and Visionary Optics’ sc
- Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosishttps://modernod.com/news/ocugen-announces-ocu400-receives-orphan-drug-designations-for-retinitis-pigmentosa-and-leber-congenital-amaurosis/2481300/Ocugen announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3)—for the treatment of retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA). “Receiving orphan drug designation is
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- EssilorLuxottica and Politecnico di Milano Launch Partnership to Develop Smart Glasses of the Futurehttps://modernod.com/news/essilorluxottica-and-politecnico-di-milano-launch-partnership-to-develop-smart-glasses-of-the-future/2480974/EssilorLuxottica and Politecnico di Milano have created the first joint research center aimed at designing the smart glasses of the future: EssilorLuxottica Smart Eyewear Lab. The agreement was announced today by Vittorio Colao, Minister for Technological Innovation and Digital Tra
- Measuring Levels of Proteins in Eye Fluid May Accurately Predict Need for Lifelong Macular Degeneration Therapyhttps://modernod.com/news/measuring-levels-of-proteins-in-eye-fluid-may-accurately-predict-need-for-lifelong-macular-degeneration-therapy/2480947/In a study of eye fluid from 38 patients, Johns Hopkins Medicine researchers say they have found that levels of a specific protein appears to help accurately predict whether people with the wet form of age-related macular degeneration (AMD) may need lifelong, frequent eye injections to preserve v
- EssilorLuxottica Chairman Leonardo Del Vecchio Passes Away at Age 87https://modernod.com/news/essilorluxottica-chairman-leonardo-del-vecchio-passes-away-at-age-87/2480931/Italian fashion icon Leonardo Del Vecchio, chairman of EssilorLuxottica, passed away at the age of 87, the company announced Monday. "The company expresses its deepest condolences to the family and to the global employee community for this enormous loss. The Board will m
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi
- FCI Ophthalmics Announces FDA Clearance of Oculid Implantable and External Eyelid Weights for the Treatment of Lagophthalmoshttps://modernod.com/news/fci-ophthalmics-announces-fda-clearance-of-oculid-implantable-and-external-eyelid-weights-for-the-treatment-of-lagophthalmos/2480641/FCI Ophthalmics announced <